MCID: PNC035
MIFTS: 89

Pancreatic Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer 53 37 12 72 49 71 36 13 13 13 51 40 14
Pancreatic Carcinoma 53 12 49 71 51 41 14 69
Pancreatic Carcinoma, Familial 12 72 69
Familial Pancreatic Carcinoma 49 55 28
Pancreatic Acinar Carcinoma 53 71
Familial Pancreatic Cancer 49 55
Carcinoma of Pancreas 12 28
Pancreatic Neoplasm 12 69
Pancreatic Tumor 12 51
Malignant Neoplasm of Body of Pancreas 12
Malignant Neoplasm of Head of Pancreas 12
Malignant Neoplasm of Tail of Pancreas 12
Hereditary Pancreatic Carcinoma 49
Malignant Neoplasm of Pancreas 69
Pancreatic Carcinoma, Somatic 53
Hereditary Pancreatic Cancer 49
Exocrine Pancreas Carcinoma 12
Pancreatic Cancer, Somatic 53
Neoplasm of the Pancreas 28
Cancer of the Pancreas 49
Pancreatic Neoplasms 41
Ca Body of Pancreas 12
Ca Head of Pancreas 12
Ca Tail of Pancreas 12
Pancreas Carcinoma 49
Pancreas Neoplasm 12
Exocrine Cancer 12
Pancreas Cancer 49
Pnca 71

Characteristics:

Orphanet epidemiological data:

55
familial pancreatic carcinoma
Inheritance: Multigenic/multifactorial; Age of onset: Adult;

OMIM:

53
Inheritance:
autosomal dominant
somatic mutation
multifactorial

Miscellaneous:
may be seen with other forms of cancer in a family


HPO:

31
pancreatic cancer:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



Summaries for Pancreatic Cancer

NIH Rare Diseases : 49 Familial pancreatic cancer (FPC) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). It is sometimes referred to as FPC only when there is not a known hereditary cancer syndrome in an affected family. In familial cases, pancreatic cancer often occurs before age 50 (earlier than other forms of pancreatic cancer). In 60% of cases it occurs within the head of the pancreas. Symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. Pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. A specific genetic cause of FPC (in the absence of a known syndrome) has not been identified. Familial cases of pancreatic cancer due to hereditary conditions may be caused by mutations in any of several genes. Individuals who carry a mutation in one of these genes are often at an increased risk of other types of cancers as well. Currently, only 10-20% of families with FPC will have a mutation identified by genetic testing. Hereditary cancer syndromes and other inherited conditions associated with pancreatic cancer include:BRCA1 hereditary breast and ovarian cancer syndrome BRCA2 hereditary breast and ovarian cancer syndrome Peutz-Jeghers syndrome FAMMM syndrome Lynch syndrome Hereditary pancreatitis In many cases, inheritance of FPC is autosomal dominant; in some cases, is may be multifactorial. It is important to note that pancreatic cancer itself is not inherited, but a genetic predisposition to developing cancer is inherited. Treatment may include surgical resection, chemotherapy, and/or radiotherapy. Resection is the only potential cure, but most patients have advanced, non-resectable tumors by the time of diagnosis. Last updated: 9/27/2016

MalaCards based summary : Pancreatic Cancer, also known as pancreatic carcinoma, is related to dysplastic nevus syndrome and pancreas adenocarcinoma, and has symptoms including back pain, abdominal pain and nausea and vomiting. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Pancreatic cancer and Signaling by GPCR. The drugs Afinitor and Erbitux have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and lung, and related phenotypes are Decreased viability and Decreased viability

OMIM : 53 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350)

UniProtKB/Swiss-Prot : 71 Pancreatic cancer: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MedlinePlus : 40 The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

Disease Ontology : 12 An endocrine gland cancer located in the pancreas.

Wikipedia : 72 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)
# Related Disease Score Top Affiliating Genes
1 dysplastic nevus syndrome 33.9 BRCA2 CDKN2A PALLD
2 pancreas adenocarcinoma 33.9 BRCA2 CDKN2A EGFR KRAS MUC4 SMAD4
3 pancreatitis, hereditary 33.3 BRCA2 MUC4 SPINK1 SST
4 adenocarcinoma 32.0 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
5 pancreatic ductal adenocarcinoma 31.7 CDKN2A EGFR KRAS MUC4 SMAD4 TP53
6 insulin-like growth factor i 31.6 EGF EGFR MAPK1 SST
7 gastric cancer 31.5 CCKBR CCND1 CDKN1A CDKN2A EGF EGFR
8 ovarian cancer 31.4 BRCA1 BRCA2 CCND1 CDKN1A EGF EGFR
9 colorectal cancer 31.3 BRCA1 BRCA2 CCKBR CCND1 CDKN1A CDKN2A
10 lynch syndrome 31.1 BRCA1 BRCA2 CCND1 CDKN2A KRAS TP53
11 breast cancer 31.1 BRCA1 BRCA2 CCND1 CDKN1A EGF EGFR
12 endometrial cancer 31.0 BRCA1 BRCA2 CCND1 CDKN1A CDKN2A EGF
13 peutz-jeghers syndrome 31.0 SMAD4 STK11 TP53
14 lung cancer 31.0 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
15 glioblastoma 31.0 BRCA2 CCND1 CDKN1A CDKN2A EGF EGFR
16 prostate cancer 31.0 BRCA1 BRCA2 CCND1 CDKN1A EGF EGFR
17 small cell cancer of the lung 30.9 CDKN2A EGFR SST TP53
18 retinoblastoma 30.8 CCND1 CDKN1A CDKN2A TP53
19 intrahepatic cholangiocarcinoma 30.8 CCND1 EGFR KRAS MUC4 TP53
20 pancreatic ductal carcinoma 30.8 CDKN2A SMAD4 TP53 VEGFA
21 glioma 30.8 CCND1 CDKN2A EGF EGFR TP53
22 basal cell carcinoma 30.8 CCND1 CDKN1A CDKN2A PALB2 TP53
23 familial adenomatous polyposis 30.7 CCND1 KRAS SMAD4 TP53
24 melanoma, cutaneous malignant 1 30.7 CDKN2A STK11 TP53
25 acinar cell carcinoma 30.7 BRCA2 SMAD4 TP53
26 cystadenocarcinoma 30.6 CDKN1A TP53 VEGFA
27 melanoma-pancreatic cancer syndrome 12.4
28 pancreatic cancer 4 12.3
29 pancreatic cancer 1 12.2
30 pancreatic cancer 3 12.2
31 pancreatic cancer 2 12.2
32 osteoclast-like giant cell neoplasm of the pancreas 12.1
33 adenosquamous pancreas carcinoma 12.0
34 pancreatic cancer, childhood 11.9
35 von hippel-lindau syndrome 11.3
36 pancreatitis 11.3
37 female reproductive organ cancer 11.1 BRCA1 BRCA2 CCND1 CDKN2A EGFR KRAS
38 reproductive organ cancer 11.1 BRCA1 BRCA2 CCND1 CDKN2A EGF EGFR
39 gastrointestinal system cancer 11.1 CCND1 CDKN1A CDKN2A EGFR KRAS SMAD4
40 esophageal cancer 11.1 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
41 hepatocellular carcinoma 11.1 CCND1 CDKN1A CDKN2A EGFR KRAS MAPK1
42 glioblastoma multiforme 11.1 CCND1 CDKN1A CDKN2A EGF EGFR MAPK1
43 cell type cancer 11.1 CCND1 CDKN2A EGF EGFR KRAS TP53
44 astrocytoma 11.1 CCND1 CDKN2A EGF EGFR KRAS TP53
45 bladder cancer 11.1 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
46 ovarian cancer 1 11.1 BRCA1 BRCA2 EGFR KRAS TP53 VEGFA
47 squamous cell carcinoma, head and neck 11.1 CCND1 CDKN1A CDKN2A EGF EGFR TP53
48 pre-malignant neoplasm 11.1 BRCA1 BRCA2 CCND1 CDKN2A EGFR TP53
49 li-fraumeni syndrome 11.1 BRCA1 BRCA2 CDKN1A CDKN2A EGFR TP53
50 oral squamous cell carcinoma 11.1 CCND1 CDKN1A CDKN2A EGFR TP53 VEGFA

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Biliary Tract Neoplasm
Cholangitis Cholestasis
Deficiency Anemia Intestinal Obstruction
Pancreatic Agenesis 1 Pancreatitis, Hereditary
Protein-Energy Malnutrition Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Symptoms via clinical synopsis from OMIM:

53
Abdomen Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma


Clinical features from OMIM:

260350

Human phenotypes related to Pancreatic Cancer:

55 31 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 back pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0003418
2 abdominal pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0002027
3 nausea and vomiting 55 31 occasional (7.5%) Occasional (29-5%) HP:0002017
4 intermittent diarrhea 55 31 occasional (7.5%) Occasional (29-5%) HP:0002254
5 hepatosplenomegaly 55 31 occasional (7.5%) Occasional (29-5%) HP:0001433
6 diabetes mellitus 55 31 occasional (7.5%) Occasional (29-5%) HP:0000819
7 weight loss 55 31 hallmark (90%) Very frequent (99-80%) HP:0001824
8 elevated hepatic transaminases 55 31 occasional (7.5%) Occasional (29-5%) HP:0002910
9 melanoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0002861
10 jaundice 55 31 frequent (33%) Frequent (79-30%) HP:0000952
11 exocrine pancreatic insufficiency 55 31 hallmark (90%) Very frequent (99-80%) HP:0001738
12 anorexia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002039
13 chronic fatigue 55 31 hallmark (90%) Very frequent (99-80%) HP:0012432
14 colon cancer 55 31 occasional (7.5%) Occasional (29-5%) HP:0003003
15 extrahepatic cholestasis 55 31 frequent (33%) Frequent (79-30%) HP:0012334
16 breast carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0003002
17 pancreatic adenocarcinoma 55 31 obligate (100%) Obligate (100%) HP:0006725
18 lymphadenopathy 55 31 frequent (33%) Frequent (79-30%) HP:0002716
19 neoplasm of the liver 55 31 occasional (7.5%) Occasional (29-5%) HP:0002896
20 functional intestinal obstruction 55 31 frequent (33%) Frequent (79-30%) HP:0005249
21 poor appetite 55 31 hallmark (90%) Very frequent (99-80%) HP:0004396
22 intestinal pseudo-obstruction 55 31 frequent (33%) Frequent (79-30%) HP:0004389
23 ovarian carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0025318
24 peritoneal abscess 55 31 occasional (7.5%) Occasional (29-5%) HP:0100592
25 neoplasm of the pancreas 31 HP:0002894

UMLS symptoms related to Pancreatic Cancer:


gastrointestinal gas, nausea and vomiting, icterus, heartburn, dyspepsia, diarrhea, constipation, abdominal pain, pruritus

GenomeRNAi Phenotypes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

25 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.02 EGFR KRAS MAPK1
2 Decreased viability GR00106-A-0 10.02 KRAS
3 Decreased viability GR00221-A-1 10.02 ACVR1B CDKN2A EGFR KRAS MAPK1
4 Decreased viability GR00221-A-2 10.02 ACVR1B KRAS
5 Decreased viability GR00221-A-3 10.02 CDKN2A MAPK1
6 Decreased viability GR00221-A-4 10.02 ACVR1B CDKN2A EGFR MAPK1
7 Decreased viability GR00231-A 10.02 MAPK1
8 Decreased viability GR00301-A 10.02 KRAS
9 Decreased viability GR00342-S-1 10.02 MAPK1
10 Decreased viability GR00342-S-2 10.02 MAPK1
11 Decreased viability GR00342-S-3 10.02 MAPK1
12 Decreased viability GR00381-A-1 10.02 KRAS
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.85 SST BRCA1 STK11 BRCA2 TP53 CDKN1A
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.85 PALB2 SST BRCA1 STK11 BRCA2 CCND1

MGI Mouse Phenotypes related to Pancreatic Cancer:

43 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.54 ACVR1B BRCA1 BRCA2 CCKBR CCND1 CDKN1A
2 digestive/alimentary MP:0005381 10.53 ACVR1B BRCA1 BRCA2 CCKBR CCND1 CDKN1A
3 cellular MP:0005384 10.49 VEGFA ACVR1B BRCA1 BRCA2 CCND1 CDKN1A
4 endocrine/exocrine gland MP:0005379 10.49 ACVR1B BRCA1 BRCA2 CCKBR CCND1 CDKN1A
5 integument MP:0010771 10.48 MAPK1 PALB2 SMAD4 SPINK1 STK11 TP53
6 behavior/neurological MP:0005386 10.47 CDKN1A CDKN2A KRAS MAPK1 PALB2 SMAD4
7 homeostasis/metabolism MP:0005376 10.47 VEGFA TP53 ACVR1B BRCA1 BRCA2 CCKBR
8 immune system MP:0005387 10.46 VEGFA BRCA1 BRCA2 CCKBR CCND1 CDKN1A
9 cardiovascular system MP:0005385 10.44 BRCA1 CCKBR CCND1 CDKN1A CDKN2A EGFR
10 embryo MP:0005380 10.44 ACVR1B BRCA1 BRCA2 CDKN1A CDKN2A EGFR
11 mortality/aging MP:0010768 10.44 ACVR1B BRCA1 BRCA2 CCND1 CDKN1A CDKN2A
12 hematopoietic system MP:0005397 10.39 SMAD4 SPINK1 STK11 TP53 VEGFA BRCA1
13 nervous system MP:0003631 10.39 CCKBR CCND1 CDKN1A CDKN2A EGFR KRAS
14 craniofacial MP:0005382 10.31 ACVR1B CCND1 CDKN1A EGFR KRAS MAPK1
15 neoplasm MP:0002006 10.29 BRCA1 BRCA2 CCND1 CDKN1A CDKN2A EGFR
16 liver/biliary system MP:0005370 10.22 CCKBR CDKN1A CDKN2A EGFR KRAS MAPK1
17 limbs/digits/tail MP:0005371 10.19 BRCA1 BRCA2 CDKN1A EGFR KRAS PALB2
18 muscle MP:0005369 10.19 BRCA1 CDKN1A CDKN2A EGFR KRAS MAPK1
19 normal MP:0002873 10.18 ACVR1B BRCA1 BRCA2 CCND1 EGF EGFR
20 no phenotypic analysis MP:0003012 10.13 ACVR1B CDKN1A CDKN2A EGFR KRAS SPINK1
21 reproductive system MP:0005389 10.1 ACVR1B BRCA1 BRCA2 CCND1 CDKN1A CDKN2A
22 renal/urinary system MP:0005367 9.97 BRCA1 CCKBR CDKN1A EGFR KRAS SMAD4
23 respiratory system MP:0005388 9.9 ACVR1B BRCA1 CCND1 CDKN1A CDKN2A EGFR
24 pigmentation MP:0001186 9.77 BRCA1 CDKN2A TP53 EGFR KRAS
25 skeleton MP:0005390 9.77 ACVR1B BRCA1 BRCA2 CCND1 CDKN1A CDKN2A
26 vision/eye MP:0005391 9.32 CCND1 CDKN1A CDKN2A EGF EGFR KRAS

Drugs & Therapeutics for Pancreatic Cancer

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 45 EVEROLIMUS Novartis March 2009
2
Erbitux 17 45 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
3
Gemzar 17 45 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
4
SecreFlo 17 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002
5
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006
6
Tarceva 17 45 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 660)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
2
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
3
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
5
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
7
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
10
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
11
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
12
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
13
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
16
Iron Approved Phase 4,Phase 2 7439-89-6 23925
17
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
18
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 46507594 772
19
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
20
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
21
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
22
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
23
Etomidate Approved Phase 4 33125-97-2 667484 36339
24
Meperidine Approved Phase 4 57-42-1 4058
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
27
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
28
Nicotine Approved Phase 4 54-11-5 89594 942
29
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
30
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
31
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 657311 5754
32
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051 23994
33
Desflurane Approved Phase 4 57041-67-5 42113
34
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
35
Thrombin Approved, Investigational Phase 4
36
Tegafur Approved, Investigational Phase 4,Phase 2,Phase 1 17902-23-7 5386
37
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
38 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
39
Butyric Acid Experimental, Investigational Phase 4,Phase 1,Phase 2 107-92-6 264
40 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
43 Hematinics Phase 4,Phase 2,Phase 3,Phase 1
44 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Phase 1
48 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2243)

# Name Status NCT ID Phase Drugs
1 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
2 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Unknown status NCT02570529 Phase 4 Albis®;Placebo
3 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
4 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
5 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
6 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
7 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
8 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
9 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
10 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
11 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
12 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
13 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
14 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
15 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
16 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
17 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
18 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
19 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
20 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
21 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
22 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
23 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
24 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
25 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
26 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
27 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
28 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
29 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
30 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
31 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
32 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
33 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Active, not recruiting NCT02238847 Phase 4
34 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
35 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
36 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
37 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
38 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
39 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Not yet recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
40 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
41 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
42 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
43 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
44 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
45 Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer Unknown status NCT02079623 Phase 3
46 Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain Unknown status NCT02510066 Phase 3
47 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
48 A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer Unknown status NCT00789633 Phase 3 masitinib (AB1010);placebo
49 Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Unknown status NCT01836432 Phase 3 FOLFIRINOX;Gemcitabine;Capecitabine;Nab-Paclitaxel
50 Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Pancreas 28 KRAS SMAD4 STK11 TP53
2 Familial Pancreatic Carcinoma 28
3 Neoplasm of the Pancreas 28

Anatomical Context for Pancreatic Cancer

MalaCards organs/tissues related to Pancreatic Cancer:

38
Pancreas, Lung, Liver, Testes, Breast, T Cells, Colon

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Cancer:

18
The Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 4600)
# Title Authors Year
1
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. ( 29441441 )
2018
2
Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. ( 29435178 )
2018
3
Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. ( 29107110 )
2018
4
A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. ( 29438371 )
2018
5
Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer. ( 28702871 )
2018
6
Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT-2 pancreatic cancer mouse model. ( 29435042 )
2018
7
Focal Autoimmune Pancreatitis Mimicking Pancreatic Cancer on FDG PET/CT Imaging. ( 29189377 )
2018
8
A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. ( 29451172 )
2018
9
Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. ( 29442211 )
2018
10
Complex HuR function in pancreatic cancer cells. ( 29452455 )
2018
11
Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma. ( 29303405 )
2018
12
TH588, an MTH1 inhibitor, enhances phenethyl isothiocyanate-induced growth inhibition in pancreatic cancer cells. ( 29435064 )
2018
13
Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. ( 29061505 )
2018
14
Counterpoint: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer. ( 29447421 )
2018
15
Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. ( 28913878 )
2018
16
Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-cohort Study in Denmark. ( 29432727 )
2018
17
POINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer. ( 29447420 )
2018
18
The application of a three-dimensional visualized seed planning and navigation system in<sup>125</sup>I seed implantation for pancreatic cancer. ( 29440912 )
2018
19
Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. ( 29180468 )
2018
20
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer. ( 29128633 )
2018
21
Treatment of pancreatic cancer with intravenous vitamin C: a case report. ( 29438178 )
2018
22
Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. ( 29445028 )
2018
23
RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. ( 29436617 )
2018
24
Localized autoimmune pancreatitis mimicking pancreatic cancer: Case report and literature review. ( 29332510 )
2018
25
Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. ( 29435118 )
2018
26
Serum Immunoglobulin G4 in Discriminating Autoimmune Pancreatitis From Pancreatic Cancer: A Diagnostic Meta-analysis. ( 29351121 )
2018
27
Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. ( 29436532 )
2018
28
Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter. ( 29451897 )
2018
29
Early Diagnosis to Improve the Poor Prognosis of Pancreatic Cancer. ( 29439461 )
2018
30
Stemness and anti-cancer drug resistance in ABCG2 highly expressed pancreatic cancer is induced on 3D-culture condition. ( 29444383 )
2018
31
Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3. ( 29137412 )
2017
32
A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer. ( 28943075 )
2017
33
Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis. ( 28079594 )
2017
34
The Transient Receptor Potential Melastatin 7 Channel Regulates Pancreatic Cancer Cell Invasion through the Hsp90I+/uPA/MMP2 pathway. ( 28284058 )
2017
35
The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study. ( 28954281 )
2017
36
Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer. ( 28303855 )
2017
37
Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). ( 28516306 )
2017
38
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. ( 28131992 )
2017
39
Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report. ( 29390348 )
2017
40
Downregulation of the N-myc downstream regulated gene 1 is related to enhanced proliferation, invasion and migration of pancreatic cancer. ( 28075464 )
2017
41
eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. ( 28381547 )
2017
42
Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. ( 28532457 )
2017
43
Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. ( 28289921 )
2017
44
YB-1 expression promotes pancreatic cancer metastasis that is inhibited by microRNA-216a. ( 28782557 )
2017
45
Effect of NR5A2 inhibition on pancreatic cancer stem cell (CSC) properties and epithelial-mesenchymal transition (EMT) markers. ( 27996162 )
2017
46
KrA1ppel-like factor 8 induces epithelial-to-mesenchymal transition and promotes invasion of pancreatic cancer cells through transcriptional activation of four and a half LIM-only protein 2. ( 28943967 )
2017
47
Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. ( 28514751 )
2017
48
ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca(2+)/RhoA pathway. ( 28518134 )
2017
49
NDRG2, suppressed expression associates with poor prognosis in pancreatic cancer, is hypermethylated in the second promoter in human gastrointestinal cancers. ( 28093228 )
2017
50
DCPP1 is the mouse ortholog of human PAUF that possesses functional analogy in pancreatic cancer. ( 28988106 )
2017